Patients should stop the medication and seek immediate medical attention for severe, persistent abdominal pain, intractable vomiting, jaundice, or signs of pancreatitis or gallbladder disease
Semaglutide weight loss in Tampa offers proven long-lasting weight loss instead of the fast and furious loss associated with other weight loss medications and fad diets
What's New: July 2026 Update TRIUMPH-4 confirmed: Retatrutide 28.7% weight loss in Phase 3 (December 2025) final data, not preliminary TRIUMPH-1 CONFIRMED (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients without diabetes pivotal trial met all primary endpoints Availability unchanged: Retatrutide still investigational, no FDA approval until late 2027 at earliest Tirzepatide still the best available option: 22.5% weight loss, FDA-approved, available today TRANSCEND-T2D-1 confirmed (June 2026): -2.0% HbA1c and 16.8% weight loss in type 2 diabetes patients a separate diabetes-specific Phase 3 program NDA timeline on track: industry estimates continue to expect Q4 2026 filing, following TRIUMPH-1's positive readout Introduction The evolution of weight loss medications has progressed rapidly from single-agonist drugs to multi-agonist approaches
Its important to note that not everyone who takes semaglutide will develop severe side effects
C-reactive protein and cardiovascular disease in people with diabetes: high-sensitivity CRP testing can help assess risk for future cardiovascular disease events in this population
